HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

myristoyl-CM4

synthetic analog generated by N-myristoylation of AMPs CM4

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Pore Forming Cytotoxic Proteins
      - Antimicrobial Cationic Peptides: 414
        myristoyl-CM4: 2
- Peptides: 82426
  - Antimicrobial Peptides: 3727
    - Antimicrobial Cationic Peptides: 414
      - myristoyl-CM4: 2
  - Antimicrobial Cationic Peptides: 414
    - myristoyl-CM4: 2

Experts

1.	Chen, Yuqing: 2 articles (01/2019 - 01/2018)
2.	Liu, Kehang: 2 articles (01/2019 - 01/2018)
3.	Lv, Tongtong: 2 articles (01/2019 - 01/2018)
4.	Xu, Xixi: 2 articles (01/2019 - 01/2018)
5.	Yang, Yunqing: 2 articles (01/2019 - 01/2018)
6.	Zhang, Huidan: 2 articles (01/2019 - 01/2018)
7.	Han, Dongju: 1 article (01/2019)
8.	Li, Caiyun: 1 article (01/2018)
9.	Liu, Hongyan: 1 article (01/2018)
10.	Zhang, Shuangquan: 1 article (01/2018)

Related Diseases

1.	Mitochondrial Diseases (Mitochondrial Disease) 01/01/2018 - "After internalization, co-localization analysis revealed that myristoyl-CM4 targeted mitochondria and induced mitochondrial dysfunction, including alterations in mitochondrial transmembrane potential, reactive oxygen species (ROS) generation and cytochrome c release. "
2.	Neoplasms (Cancer) 01/01/2018 - "Here we show that myristoyl-CM4, a new synthetic analog generated by N-myristoylation of AMPs CM4, had anticancer activity against MCF-7, MDA-MB-231, MX-1 breast cancer cells (IC50 of 3-6 μM) and MDA-MB-231 xenograft tumors. "
3.	Necrosis 01/01/2019 - "Conclusion: These results suggested that myristoyl-CM4 showed selective cytotoxicity to leukemia K562/MDR and Jurkat cells by apoptosis and/or necrosis pathway. " 01/01/2019 - "Myristoyl-CM4 also induced K562/MDR cell necrosis by directive membrane disruption, and significantly decreased the level of P-glycoprotein in K562/MDR cells. "
4.	Leukemia 01/01/2019 - "Myristoyl-CM4, thus, appears to be a promising candidate for leukemia treatment, including multidrug-resistant leukemia." 01/01/2019 - "The myristoyl group effectively mediated the internalization of myristoyl-CM4 to leukemia cells. " 01/01/2019 - "Conclusion: These results suggested that myristoyl-CM4 showed selective cytotoxicity to leukemia K562/MDR and Jurkat cells by apoptosis and/or necrosis pathway. "
5.	Breast Neoplasms (Breast Cancer) 01/01/2018 - "Despite increasing cytotoxicity against HEK293 and NIH3T3 cells and erythrocytes associated with its anticancer activity, myristoyl-CM4 maintained a certain selectivity toward breast cancer cells. " 01/01/2018 - "Here we show that myristoyl-CM4, a new synthetic analog generated by N-myristoylation of AMPs CM4, had anticancer activity against MCF-7, MDA-MB-231, MX-1 breast cancer cells (IC50 of 3-6 μM) and MDA-MB-231 xenograft tumors. " 01/01/2018 - "Glycosylation analysis showed that sialic acid-containing oligosaccharides (including O-mucin and gangliosides) were important targets for myristoyl-CM4 binding to breast cancer cells. "

Related Drugs and Biologics

1.	Cytochromes c (Cytochrome c)
2.	Member 1 Subfamily B ATP Binding Cassette Transporter
3.	N-Acetylneuraminic Acid (Sialic Acid)
4.	Reactive Oxygen Species (Oxygen Radicals)
5.	Oligosaccharides
6.	Mucins
7.	Gangliosides